CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services Drug Reimbursement Review encorafenib
Back to Programs and Services

Drug Reimbursement Review

encorafenib

Last Updated: November 20, 2020
Result type: Reports
Project Number: PC0233-000
Product Line: Reimbursement Review

Generic Name: encorafenib

Brand Name: Braftovi

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Metastatic colorectal cancer

Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.

Manufacturer Requested Reimbursement Criteria1: In combination with cetuximab or panitumumab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAFV600E mutation, after prior therapy.

Submission Type: Initial

Tumour Type: Gastrointestinal

Project Status: Pending

Call for patient/clinician input open: November 17, 2020

Call for patient/clinician input closed: January 15, 2021

Anticipated Date: December 15, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback